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ArsA is the catalytic subunit of the arsenical pump,
coupling ATP hydrolysis to the efflux of arsenicals
through the ArsB membrane protein. It is a paradigm
for understanding the structure-function of the nucleo-
tide binding domains (NBD) of medically important ef-
flux pumps, such as P-glycoprotein, because it has two
sequence-related, interacting NBD, for which the struc-
ture is known. On the basis of a rigorous analysis of the
pre-steady-state kinetics of nucleotide binding and hy-
drolysis, we propose a model in which ArsA alternates
between two mutually exclusive conformations as fol-
lows: the ArsA1 conformation in which the A1 site is
closed but the A2 site open; and the ArsA2 conformation,
in which the A1 and A2 sites are open and closed, respec-
tively. Antimonite elicits its effects by sequestering ArsA
in the ArsA1 conformation, which catalyzes rapid ATP
hydrolysis at the A2 site to drive ArsA between confor-
mations that have high (nucleotide-bound ArsA) and low
affinity (nucleotide-free ArsA) for Sb(III). ArsA poten-
tially utilizes this process to sequester Sb(III) from the
medium and eject it into the channel of ArsB.
One of the most frequently employed strategies to gain
resistance to cytotoxic compounds in both eukaryotes and
prokaryotes is the active extrusion of these compounds from
the cell to reduce the intracellular concentration to subtoxic
levels (1). Protein pumps that span the membrane catalyze
this extrusion process, and many of them belong to the ATP-
binding cassette (ABC)1 superfamily (2). This family includes
the human multidrug resistance P-glycoprotein, which con-
fers resistance to anti-cancer drugs (2), and homologues from
bacteria (3, 4), fungi (5), and protozoa (6). Generally, these
ABC transporters are composed of two homologous halves,
each containing two parts as follows: a transmembrane do-
main putatively arranged into 6 a-helices and a nucleotide
binding domain (NBD).
Our understanding of the mode of operation of these efflux
pumps is still rudimentary, and several fundamental questions
concerning their function need to be answered if we are to
design inhibitors that block these pumps, allowing us to over-
come multidrug resistance. For example, since most, if not all,
ABC drug transporters have two nucleotide-binding sites
(NBS), it is of importance to determine whether these sites are
functionally equivalent. Biochemical studies of P-glycoprotein
indicate that both NBS can hydrolyze ATP, but substrate-
stimulated ATPase activity requires interaction between the
two halves of the molecule (7). Inactivation by chemical modi-
fication or mutagenesis of either NBS causes a loss of activity,
suggesting cooperativity between the sites (8, 9), and it has
been suggested that the sites function by an alternating site
mechanism (10). P-glycoprotein has been overexpressed and
can be purified as a functional ATPase in low concentration of
detergent, enabling biophysical studies of the protein (11). The
binding of fluorescent analogues of ATP to the protein indi-
cated that there is a single class of site, suggesting that the two
NBS are equivalent. Perhaps this is not surprising because the
NBS have similar sequences. Although the NBS of P-glycopro-
tein resemble one another, this is not the case for other mam-
malian ABC drug transporters, such as multidrug resistance
protein 1, and recent studies have shown that the NBS of
multidrug resistance protein 1 are nonequivalent (12, 13).
Clearly, to understand fully how the NBS interact will require
structural information. A recent advance in our understanding
has come from the determination, by x-ray crystallography, of
the structure of HisP (14, 15), the ATPase subunit of the
histidine permease, a bacterial ABC transporter that catalyzes
the uptake of histidine. Although arranging the monomeric
HisP into a dimer is speculative, the structure predicts that the
two nucleotide-binding sites are orientated away from one an-
other. Inactivation of one of these sites results in a transporter
that has half the ATPase and transport activity of the wild-type
protein complex (16), suggesting that there is little or no coop-
erativity between these sites. This may represent a real differ-
ence with P-glycoprotein, because cross-linking studies have
shown that the NBS of P-glycoprotein are in close proximity
(17). In addition, the NBD of P-glycoprotein has a site for
ligands, such as flavonoids, that modulate drug transport,
probably by inhibiting the ATPase activity (18). Unfortunately,
we do not have a view of the structure of P-glycoprotein at
atomic resolution, and at the present we must glean informa-
tion from other efflux pumps that have proved more amenable
to structure-function studies.
The ArsAB ATPase is a prokaryotic pump that exhibits
structural and functional similarity to P-glycoprotein (19).
They are both efflux pumps for multiple forms of toxic com-
pounds, have two similar consensus nucleotide binding do-
mains, are substrate-dependent ATPases, have 12 membrane-
spanning a-helices arranged in two groups of six, and their
NBDs contain allosteric sites. As such, the arsenical pump is a
useful model for the study of the molecular mechanism of
resistance pumps. However, the arsenical pump is composed of
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two proteins, ArsA and ArsB; ArsA is the 63-kDa catalytic
subunit that couples ATP hydrolysis to oxyanion translocation,
whereas ArsB is the 45-kDa membrane sector of the pump, a
12-helix protein that acts as the oxyanion-translocating sector
of the pump. ArsA is normally bound to ArsB but can be
purified as a soluble ATPase in the absence of ArsB, facilitating
detailed studies of its structure-function. ArsA is arranged into
two homologous halves, the N-terminal (A1) (residues 1–282)
and C-terminal (A2) (residues 321–583) domains, which are
connected by a flexible 25-residue linker (residues 283–320)
(19), and each domain has a consensus NBD. Site-directed
mutagenesis of these sequences indicates that both NBDs are
required for both catalysis and resistance (20, 21). On the basis
of genetic studies, the A1 and A2 NBDs have been shown to
interact during catalysis (22, 23) and exhibit strong positive
cooperativity (24). The ArsA ATPase is allosterically regulated
by its substrate metalloids As(III) and Sb(III) (1). This is sim-
ilar to the allosteric activation of the P-glycoprotein by drug
substrates (1) and may be a common feature of ABC transport-
ers. Indeed, bacterial ABC transporters frequently include
ATPase subunits with an allosteric site that controls the
ATPase activity (4). In a most important advance, the structure
of ArsA has been determined to atomic resolution (25). The
structure of ArsA indicates that the A1 and A2 halves of ArsA
are arranged into two domains, with the NBS formed from
residues contributed from both domains and are located at the
interface between them in close proximity to one another.
These structural and functional properties of ArsA indicate
that the NBS are likely to resemble those in P-glycoprotein and
certainly more so than HisP. In common with P-glycoprotein,
the NBD of ArsA are in close proximity, face one another, and
interactions between them are necessary to support ATPase
activity and transport.
Previously, we established that the tryptophan fluorescence
of W159H6 ArsA was far more responsive to the binding of the
substrate MgATP than the product MgADP, allowing us to
exploit this behavior in elucidating the substrate binding, but
not the product release, steps of the ATPase mechanism by
stopped-flow fluorescence spectroscopy (19, 26, 27). In contrast,
the W141H6 ArsA is more responsive to the binding of the
product MgADP than the substrate MgATP (28), and here we
exploit this behavior in elucidating the product release steps of
the ATPase mechanism.
MATERIALS AND METHODS
Purification of His6-tagged ArsA ATPase—W141H6 ArsA and
W159H6 ArsA were purified as described previously (28), quickly fro-
zen, and stored in small aliquots at 280 °C. The concentration of puri-
fied ArsA was determined by UV absorbance at 280 nm. The extinction
coefficients for W141H6 ArsA and W159H6 ArsA were calculated to be
21,530 and 20,250 M21 cm21, respectively (28).
Fluorescence Measurements—An Applied Photophysics (London,
UK) SX.18MV stopped-flow instrument, operated at 20 °C, was used
to monitor ligand-induced changes in the steady-state fluorescence of
ArsA with time. For measurements of the change in tryptophan
fluorescence, the samples were excited with light at 292.5 nm, se-
lected with a monochromator, and the emission monitored at wave-
lengths above 335 nm, using a cut-off filter. For measurements of the
change in MANT fluorescence, the samples were excited with light at
292.5 nm, selected with a monochromator, and the emission moni-
tored at wavelengths above 420 nm, using a cut-off filter. Invariably,
equal volumes of the reactants were mixed together in the stopped-
flow instrument, using two syringes of equal volume. The concentra-
tion of ArsA was 5 mM, unless otherwise noted, in 50 mM MOPS-KOH
(pH 7.5), 0.25 mM EDTA. All concentrations are for the mixing cham-
ber, unless stated otherwise, so that the concentrations in the syringe
were twice those quoted for the mixing chamber. The base-line fluo-
rescence was generally set by mixing 5 mM ArsA with buffer and
increasing the photomultiplier tube voltage to a level that would give
a 4-V signal and ligand-induced changes in fluorescence measured
relative to this signal (i.e. an increase in the signal from 4 to 4.1 V
would correspond to a 2.5% increase in fluorescence and from 4 to 3.9
V a 2.5% quench in fluorescence). Since some of the experiments were
conducted over a long time base, we decided to test for photobleaching
of the protein by monitoring the fluorescence of ArsA, mixed with
buffer in the stopped-flow instrument, over 1000 s; no decay in the
protein fluorescence was observed over this time. As a routine second
check of fluorescence signals that decay over 1000 s, we have closed
the lamp shutter during data acquisition for about 100–200 s and
then re-opened it before the end of the reaction. In this manner we
have been able to check that the signal continues to decay in the
absence of light, indicating that it represents a true ligand-induced
change in the protein fluorescence rather than photobleaching. Since
ADP inner-filter effects would tend to reduce the signal size for the
high concentrations of ADP used in some of the assays, we conducted
the following experiment to measure the inner-filter effect for a series
of ADP concentrations, bovine serum albumin was mixed with in-
creasing concentrations of ADP up to 5 mM, and the drop in base-line
signal was recorded. An inner-filter effect was observed, but it was
much less severe than observed in a conventional fluorimeter, in-
creasing linearly over the studied range, with concentrations below 5
mM decreasing the base-line signal by less than 10%. The experiment
was also repeated with ArsA W159H6, which is optically unrespon-
sive to the binding of ADP (28), indicating a similar inner-filter effect.
Accordingly, data points were corrected for this small inner-filter
effect.
Data Analysis—Stopped-flow traces, generated using a logarithmic
time base (29), were analyzed by fitting to single (e.g. s 5 Azexp2kt;
where s represents the change in signal (e.g. volts or % fluorescence),
t the time, A and k the amplitude and rate constant for the signal
change, respectively) or multiple exponential functions (e.g. s 5
A1zexp
2k (1)t 1 A2zexp
2k (2)t 1 A3zexp
2k (3)t, for a triple exponential
function) using the nonlinear regression software with the Applied
Photophysics stopped-flow. As a guide to the adequacy of a particular
equation to define a data set, we increased the number of exponential
parameters within the equation until the data points were randomly
distributed about the best fit line in a plot of the residual variance.
Concentration dependence data were analyzed by nonlinear regres-
sion fitting to hyperbolic functions, using SIGMAPLOT 4.0. Kinetic
simulations were set up using the program Pro-K (Applied Photo-
physics), which uses the Marquardt-Levenberg algorithm for global
optimization of the reaction parameters.
ATPase Assays—A continuous assay was used to monitor phosphate
production by ArsA. Essentially, the absorbance change at 360 nm
associated with the phosphorolysis of 2-amino-6-mercapto-7-methylpu-
rine by the inorganic phosphate generated by the ATPase activity was
monitored (26). The phosphorolysis reaction was catalyzed by purine
nucleotide phosphorylase. The components of the assay were provided
as part of an EnzCheck phosphate assay kit (Molecular Probes, Eugene,
OR) and used according to the manufacturer’s recommendations. As-
says were performed in 40 mM Tris-HCl (pH 7.5), 2 mM MgCl2, contain-
ing 0.2 mM sodium azide. The change in absorbance with time was
measured in a Unicam (UV2) UV-visible spectrometer. Absorbance
changes were converted into phosphate concentrations with DE360 5 12
mM21zcm21. For stopped-flow studies, both syringes contained the com-
ponents of the reaction kit, but one syringe contained 10 mM ArsA and
the other 1 mM MgATP.
RESULTS
MgADP Binding to ArsA—The binding of MgADP to
W141H6 ArsA causes a quench in the tryptophan fluorescence
of the protein that can be time-resolved by stopped-flow fluo-
rescence spectroscopy. Fig. 1 shows representative stopped-
flow records for the mixing of 5 mM W141H6 ArsA with ADP/5
mM MgCl2. In each case the profile was clearly multiphasic,
with a very fast (t1⁄2 ,2 ms) phase that was well resolved from
a slow decay over 1000 s. Overall, the traces could be fitted to
a 4-exponential function, indicative of four phases with t1⁄2 ,1
ms, t1⁄2 ,2 s, t1⁄2 ,40 s, and t1⁄2 ,400 s, respectively. However, we
found that as the ADP concentration was increased a 5-expo-
nential function gave a better fit because of the appearance of
a phase with a t1⁄2 ,3 ms. Although this phase involved an
increase in fluorescence, this was only slight and not well
resolved from the very fast decrease in fluorescence at low ADP
concentrations.
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As shown in Fig. 1, only the rate and amplitude of the very
fast phase varied with the ADP concentration, indicating
that the slower phases were due to isomerizations of the
ArsA-ADP complex. The rate constant for the very fast phase
increased in a hyperbolic manner with the MgADP concen-
tration (Fig. 2A). A fit of the rate data to the following
hyperbolic Equation 1,
kobs 5
kmax z @ADP]
Kd 1 @ADP#
1 kmin (Eq. 1)
indicated maximal (kmax) and minimal (kmin) rates of binding
of 600 (6 20) and 30 (6 20) s21, respectively, and a Kd of 600
(6 100) mM. This behavior is consistent with the fast phase
attributable to a two-step binding process shown in Scheme
1,
ArsA2 1 MgADP9|=
k22
k2@MgADP#
ArsA3-MgADP9|=
k23
k3
ArsA4-MgADP
SCHEME 1
where the first step is a rapid equilibrium binding of MgADP to
ArsA, followed by a rate-limiting isomerization of the ArsA-
MgADP complex. Applying Equation 1 to Scheme 1, Kd is
equivalent to 1/K2 (5 k22/k2), kmax 5 k3 1 k23 and kmin 5 k23.
The overall equilibrium constant is a function of both K2 and K3
(Equation 2),
Kd 5
~1/K2!
~1 1 K3!
(Eq. 2)
where K2 5 0.6 mM and K3 5 k3/k23 5 600/30 5 20. Thus, the
apparent Kd value can be calculated as 24 mM. However, a plot
of the amplitude data (Fig. 2B), which will provide a measure of
the overall Kd, yielded a value of 800 (6 100) mM. A plausible
explanation for this behavior is that the ArsA exists in two
rapidly inter-converting conformational forms that differ in
FIG. 1. MgADP-induced conformational changes in ArsA. In the
upper panel two semi-logarithmic plots of stopped-flow traces generated
by mixing 5 mM ArsA with 1 mM ADP, 5 mM MgCl2 (trace A) and 5 mM
ArsA with 0.05 mM ADP, 5 mM MgCl2 (trace B) are shown. Changes in
the ArsA fluorescence were recorded with Ex 5 292.5 nm and Em .335
nm, and one vertical division represents a fluorescence change of 5%.
The smooth curve through each trace is the best fit to a 4-exponential
equation with rate constants of 510 (6 40), 0.14 (6 0.02), 0.030 (6
0.002), and 0.0020 (6 0.0001) s21 (trace A); and 84 (6 4), 0.20 (6 0.02),
0.021 (6 0.001), and 0.0020 (6 0.0001) s21 (trace B). In the lower panel,
trace A is plotted on a linear time scale, with the first 50 ms of the
reaction shown as an inset. The smooth curve through the trace is the
best fit to the 4-exponential equation defined for trace A in the top
panel. Clearly, the fitted equation provides an adequate fit of the data
at both the early and late data points, as indicated by the best fit line
and, as shown in the bottom panel, a plot of the residual variance of the
data about the best fit curve. One vertical division represents a fluo-
rescence change of 2.5% and 1.25% for the inset.
FIG. 2. The concentration dependence of the rate of binding of
MgADP to ArsA. A series of stopped-flow records were generated by
mixing ArsA with 5 mM MgCl2 and ADP, at the indicated concentration,
in a stopped-flow device. The rate (A) and amplitude (B) of the fluores-
cence signal for the binding of MgADP to ArsA are plotted as a function
of the ADP concentration. The curves through the data points are the
best fits to a hyperbolic equation, indicating values of 600 (6 20) s21, 30
(6 20) s21, and 600 (6 100) mM for kmax, kmin, and Kd, respectively, in A,
and of 800 mM (6 100) and 26% (6 1) for the Kd and maximal fluores-
cence change (Fmax) in B.
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their affinities for MgADP (Scheme 2),
ArsA19|=
K1
ArsA2 1 MgADP9|=
K2
ArsA3-MgADP9|=
K3
ArsA3-MgADP
SCHEME 2
The overall Kd value is a function of K1, K2, and K3 (Equation
3),
Kd 5
1
K2
z
~1 1 K1!
~1 1 K3!
(Eq. 3)
Accordingly, K1 can be calculated, from the overall Kd and K2,
as 27, indicating that 96% of the ArsA is in the ArsA1 confor-
mation prior to the binding of MgADP.
Dissociation of the ArsA-MgADP Complex—We attempted to
measure the rate constant for the dissociation of MgADP from
the ArsA-MgADP complex by displacement with MANT-ADP.
As shown in Fig. 3A, when 5 mM ArsA, 0.5 mM MgADP was
mixed with 125 mM MANT-ADP, 5 mM MgCl2 there was an
increase in MANT fluorescence, indicating that the ADP had
been replaced. However, an identical trace was obtained when
the ADP was included with the MANT-ADP (Fig. 3C), rather
than with the ArsA, during the mixing experiment. This be-
havior suggests that the ADP can rapidly dissociate from the
ArsA and competes with MANT-ADP for binding to ArsA. For
this to occur, ADP dissociation must be faster than the binding
of MANT-ATP to ArsA (e.g. 223 s21 for 125 mM MANT-ATP
(Fig. 3B)).2 In contrast, extrapolation of the data in Fig. 2 to the
y axis suggested a much slower rate of dissociation (e.g. k 5 30
(6 20) s21). Conceivably, this might provide a measure of k23
rather than k22 in Scheme 1, but it could also arise if the two
NBS had different affinities (see below).
Mg21 Binding to ArsA-ADP—In a parallel set of experi-
ments, the binding of Mg21 to the W141H6 ArsA-ADP complex
was investigated, revealing a similar behavior; formation of the
ArsA-MgADP complex led to a fast quench in fluorescence,
followed by a slow decay over several minutes (Fig. 4). Only the
rate of the fast phase was dependent upon the ADP concentra-
tion, suggesting that the three slow phases are attributable to
isomerizations of the ArsA-MgADP complex (data not shown).
The rate of the fast phase increased in a hyperbolic manner
(Fig. 5A), deviating only slightly at high concentrations, and
the early data points were best fit to a hyperbolic equation with
a zero intercept (Equation 4),
kobs 5
kmax z [ADP]
Kd 1 [ADP]
(Eq. 4)
Thus, the fit yielded a Kd of 90 (6 10) mM and a maximal rate
of binding of 170 (6 10) s21. This analysis indicated that the
back rate, determined from the intercept of the y axis, was too
slow for accurate determination. A possible explanation for
the relatively high affinity binding might be that ADP alone
stabilizes the ArsA2 conformation. Consistent with this pre-
diction, the amplitude data indicated a Kd of 190 (6 20) mM
and a maximal quench in fluorescence (Fmax) of 29 (6 1)%
(Fig. 5B).
The relatively slow rate constant for formation of the ArsA-
MgADP complex from ArsA-ADP and Mg21 (e.g. kmax 5 170 (6
10) s21), as compared with that from ArsA and MgADP (e.g.
kmax 5 600 (6 100) s
21), indicates a more complex binding
process than the simple addition of Mg21 to the ArsA-ADP
complex. The Mg21 cannot bind directly to the ArsA2-ADP
complex, nor can complex formation be rate-limited by ADP
dissociation from ArsA2, otherwise the rate of complex forma-
tion would be independent of the ADP concentration. A plau-
sible explanation of this kinetic behavior is that at sufficiently
high concentrations of ADP, when the binding of MgADP would
be faster than the dissociation of ADP from the ArsA2-ADP
complex, ADP dissociation becomes rate-limiting. Thus inter-
preting the data implies that ADP dissociates from the ArsA-
ADP complex with a rate constant of 170 s21.
ADP Dissociation from the ArsA-ADP Complex—To test the
2 This experiment was repeated for several lower concentrations of
ADP with the same result that MgADP dissociation is rapid compared
with the rate of binding of MANT-ATP to ArsA.
FIG. 3. The dissociation of the ArsA-MgADP complex induced
by MANT-ADP displacement. Three semi-logarithmic plots of
stopped-flow traces generated by mixing 5 mM ArsA, 0.5 mM ADP, 5 mM
MgCl2 with 0.125 mM MANT-ADP, 5 mM MgCl2 (A); 5 mM ArsA, 5 mM
MgCl2 with 0.5 mM ADP, 0.125 mM MANT-ADP, 5 mM MgCl2 (B); and
5 mM ArsA, 5 mM MgCl2 with 0.125 mM MANT-ADP, 5 mM MgCl2 (C) are
shown. Changes in the ArsA fluorescence were recorded with Ex 5
292.5 nm and Em . 420 nm, and one vertical division represents a
fluorescence change of 2.5%. The smooth curve through traces A and B
are the best fits to a 3-exponential equation with rate constants of 36 (6
1), 1.9 (6 0.1), and 0.09 (6 0.01) s21 (A) and 22 (6 2), 7.8 (6 0.3), and
0.094 (6 0.005) s21 (B).
FIG. 4. Mg21-induced conformational changes in the ArsA-ADP
complex. A semi-logarithmic plot of a stopped-flow trace generated by
mixing 5 mM ArsA, 0.5 mM ADP with 5 mM MgCl2. Changes in the ArsA
fluorescence were recorded with Ex 5 292.5 nm and Em . 335 nm, and
one vertical division represents a fluorescence change of 2.5%. The
smooth curve through each trace is the best fit to a 4-exponential
equation with rate constants of 139 (6 3), 2.3 (6 0.3), 0.050 (6 0.003),
and 0.0020 (6 0.0001) s21.
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prediction that ADP dissociation from ArsA2 becomes rate-
limiting at high ADP concentrations, we attempted to measure
the ADP dissociation rate constant, in the absence of Mg21, by
displacement with MANT-ADP. The binding of MANT-ADP to
ArsA induced a rapid increase in MANT fluorescence, followed
by a slower increase, which was best fit to a 4-exponential
function, yielding a rate constant of 350 (6 10) s21 for the fast
phase (Fig. 6A). In contrast, when ArsA was preincubated with
ADP, before mixing with MANT-ADP, only the rapid increase
in MANT fluorescence was apparent, although the data were
best fit to a double exponential function, with the fast phase
occurring with a rate constant of 170 (6 40) s21 (Fig. 6B). It is
most likely that the difference in reaction profiles is attribut-
able to dissociation of the ArsA-ADP complex rate-limiting the
binding of MANT-ADP. A proposal that was supported by the
fact that a similar trace to that obtained for the binding of
MANT-ADP alone was obtained when ArsA was mixed with
MANT-ADP/ADP (Fig. 6C). Although, as expected, preincubat-
ing the MANT-ADP with ADP caused a reduction in the signal
amplitude and yielded a slower rate constant, this is consistent
with the ADP competing with the MANT-ADP for binding to
ArsA. We conclude that ADP dissociates from ArsA with a rate
constant of 170–200 s21. This conclusion is further supported
by the fact that reducing the ADP concentration with which the
ArsA was preincubated from 0.5 to 0.25 mM had no effect upon
the apparent rate constant for the binding of MANT-ADP (data
not shown).
The data presented herein supports the existence of an ArsA-
ADP complex, and the value obtained for the rate constant for
the dissociation of ADP is comparable with that determined for
the maximal rate of formation of the ArsA-MgADP binary
complex from ArsA-ADP and Mg21. Accordingly, this behavior
is consistent with the rate-limiting dissociation of ADP from
ArsA during the formation of the ArsA-MgADP complex from
ArsA-ADP and Mg21.
Mg21 Dissociation from the ArsA-MgADP Complex—The de-
crease in the tryptophan fluorescence upon formation of the
ArsA-MgADP complex can be reversed by mixing with EDTA,
suggesting that ADP is released as EDTA chelates the Mg21.
The stopped-flow trace shown in Fig. 7B, for the mixing of 5 mM
ArsA, 0.5 mM ADP, 5 mM MgCl2 with 20 mM EDTA, was best fit
to a double exponential function, with rate constants of 6.6 and
0.17 s21, and relative signal amplitudes of 0.9 and 0.1, respec-
tively, giving a total fluorescence change of 22%. This value for
the increase in fluorescence is comparable to the decrease in
fluorescence for the binding of Mg21 to the ArsA-ADP (e.g. 5 mM
ArsA/0.5 mM ADP) complex (cf. 22 versus 21%), indicating that
the 20 mM EDTA caused the ArsA-MgADP complex to fully
dissociate.3 The dominant phase, which occurred with a rate
constant of 6.6 s21, must be attributable to the dissociation of
the complex because there are no isomerizations of a compara-
ble rate for ternary complex formation from ArsA/ADP and
Mg21 (e.g. see Fig. 4). The slow rate of dissociation suggests
that the ArsA-MgADP complex is relatively stable. Indeed,
dilution of the ArsA-MgADP complex, by mixing with buffer in
the stopped-flow, was insufficient to dissociate the complex
(Fig. 7E). These data raise an apparent anomaly because the
binding of MgMANT-ADP to ArsA is not rate-limited by the
dissociation of the ArsA-MgADP complex (e.g. see Fig. 3). A
simple explanation for this behavior is that the A1 and A2 NBS
have different affinities. EDTA is necessary to induce dissoci-
ation of MgADP from the high affinity site, but MANT-ADP can
displace MgADP from the low affinity site. Since the trypto-
phan residue that acts as the reporter of the EDTA effects is
positioned in the A1 domain, this suggests that the A1 site has
greater affinity than the A2 site.
Sb(III) Binding to ArsA—The binding of Sb(III) to ArsA
induced a small quench in the tryptophan fluorescence, indic-
ative of the formation of an ArsA-Sb(III) complex (Fig. 8A). The
stopped-flow traces were best fit to a triple exponential func-
tion with rate constants of about 20, 0.3, and 0.03 s21, which
were independent of the Sb(III) concentration (data not shown).
However, a very rapid increase in fluorescence was noted for
the higher concentrations of Sb(III) used, which might be due
to the binding of Sb(III), followed by three slow isomerizations
of the ArsA-Sb(III) complex. A hyperbolic fit of the total ampli-
tude of the signal indicated a Kd of 540 mM and a maximal
quench of 5% (data not shown), indicating that Sb(III) is bound
with low affinity in the absence of nucleotides (see below).
Sb(III) Binding to the ArsA-MgADP Complex—The binding
of Sb(III) to the ArsA-MgADP complex was characterized by
a rapid decrease in tryptophan fluorescence (e.g. t1⁄2 ,50 ms,
DF ,5%), followed by a slow decay in fluorescence over sev-
3 A signal of comparable amplitude and rate was obtained when 100
mM EDTA was used to induce dissociation of the ArsA-MgADP complex
(Fig. 7A).
FIG. 5. The ADP concentration dependence of the rate of for-
mation of the ArsA-MgADP complex induced by the binding of
Mg21 to the ArsA-ADP complex. A series of stopped-flow records
were generated by mixing ArsA, equilibrated with ADP at the indicated
concentration, with 5 mM MgCl2 in a stopped-flow device. The rate (A)
and amplitude (B) of the fluorescence signal for the formation of the
ArsA-MgADP complex are plotted as a function of the ADP concentra-
tion. The curves through the data points are the best fits to a hyperbolic
equation, indicating values of 170 (6 10) s21 and 90 (6 10) mM for kmax
and Kd, respectively, in A, and of 190 mM (6 20) and 29% (6 1) for the
Kd and maximal fluorescence change (Fmax) in B.
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eral minutes (Fig. 8B). Sb(III) did not reverse the quench in
tryptophan fluorescence caused by the binding of MgADP to
ArsA, and we attribute the decrease in fluorescence to the
formation of an ArsA-MgADP-Sb(III) complex. Furthermore,
as discussed below, EDTA can reverse the quench in fluores-
cence of this complex, confirming its identity as the ArsA-
MgADP-Sb(III) complex. For most stopped-flow traces, the
data were adequately fitted to a triple exponential function
(e.g. Fig. 8C), but as the Sb(III) concentration was increased
there was a deviation of the early part of the trace from this
function (e.g. Fig. 8B). This is suggestive of the presence of a
faster phase, but since this was not well resolved all the
traces were fitted to triple exponential functions. As indi-
cated by Fig. 8, B and C, the most pronounced change, with
the Sb(III) concentration, was in the rate and amplitude of
the fast phase, and we attribute this phase to the formation
of the ArsA-MgADP-Sb(III) complex. The rate of complex
formation increased in a hyperbolic manner, and the data
were best fit to a hyperbolic equation (e.g. Equatrion 1),
yielding values for kmax, kmin, and Kd of 80 (6 10) s
21, 3 (6 1)
s21, and 60 (6 20) mM, respectively (Fig. 9A). Applying Equa-
tion 2 yielded a value of 2 mM for the overall Kd. On the other
hand, a fit of the amplitude data (Fig. 9B) to a hyperbolic
FIG. 6. The dissociation of the ArsA-
ADP complex induced by MANT-ADP
displacement. Three semi-logarithmic
plots of stopped-flow traces generated by
mixing 5 mM ArsA with 62.5 mM MANT-
ADP (A), 5 mM ArsA, 0.5 mM ADP with
62.5 mM MANT-ADP (B), and 5 mM ArsA
with 0.5 mM ADP, 62.5 mM MANT-ADP
(C) are shown. Changes in the ArsA fluo-
rescence were recorded with Ex 5 292.5
nm and Em . 420 nm, and one vertical
division represents a fluorescence change
of 2.5%. The smooth curve through traces
A and C is the best fit to a 4-exponential
equation with rate constants of 400 (6
100), 24 (6 1), 0.73 (6 0.03), and 0.045 (6
0.001) s21 (A); and 350 (6 10), 24 (6 1),
0.83 (6 0.03), and 0.046 (6 0.001) s21 (C).
The smooth curve through trace B is the
best fit to a double exponential equation
with rate constants of 170 (6 40) and 14.8
(6 0.4) s21, where the fast phase repre-
sents 78% of the total signal amplitude.
FIG. 7. EDTA-induced dissociation of the ArsA-MgADP and
ArsA-MgADP-Sb(III) complexes. A set of semi-logarithmic plots of
stopped-flow traces generated by mixing 5 mM ArsA, 0.5 mM ADP, 5 mM
MgCl2 with 100 mM EDTA (A); 5 mM ArsA, 0.5 mM ADP, 5 mM MgCl2
with 20 mM EDTA (B); 5 mM ArsA, 0.5 mM ADP, 5 mM MgCl2, 0.1 mM
Sb(III) with 20 mM EDTA (C); 5 mM ArsA, 0.5 mM ADP, 5 mM MgCl2, 2.5
mM Sb(III) with 20 mM EDTA (D); and 5 mM ArsA, 0.5 mM ADP, 5 mM
MgCl2 with buffer (E) are shown. Changes in the ArsA fluorescence
were recorded with Ex 5 292.5 nm and Em . 335 nm. One vertical
division represents a fluorescence change of 5%. The smooth curves
through traces B and C are the best fits to a double exponential equation
with rate constants of 6.60 (6 0.02) and 0.170 (6 0.004) s21 (B); and 2.50
(6 0.03) and 0.48 (6 0.01) s21 (C). The data imply that Sb(III) retards
the dissociation of the ArsA-MgADP-Sb(III) complex. Note that traces A
and E are displaced from the other for clarity of presentation.
FIG. 8. Antimonite-induced conformational changes in ArsA
and the ArsA-MgADP complex. A set of semi-logarithmic plots of
stopped-flow traces generated by mixing 5 mM ArsA with 2.5 mM Sb(III)
(A); 5 mM ArsA, 1 mM ADP, 5 mM Mg21 with 1.5 mM Sb(III) (B); and 5
mM ArsA, 1 mM ADP, 5 mM Mg21 with 50 mM Sb(III) (C), are shown.
Changes in the ArsA fluorescence were recorded with Ex 5 292.5 nm
and Em . 335 nm. One vertical division represents a fluorescence
change of 2.5%. The smooth curve through each trace is the best fit to
a 3-exponential equation with rate constants of 21 (6 1), 0.31 (6 0.02),
and 0.031 (6 0.003) s21 (A); 89 (6 1), 3.2 (6 0.1), and 0.08 (6 0.01) s21
(B); and 39.1 (6 0.4), 1.20 (6 0.03), and 0.044 (6 0.004) s21 (C).
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equation yielded an overall Kd of 30 (6 3) mM,
4 suggesting
that the ArsA-MgADP complex exists in equilibrium between
forms that have high and low affinity (e.g. K1 5 10) for
Sb(III). This is perhaps not surprising because the unligan-
ded ArsA exists in two forms that differ in their affinity for
MgADP. Although less pronounced, the rates of the interme-
diate and slow phases increased in a hyperbolic manner with
the antimonite concentration, indicating Kd values of 200 (6
100) and 300 (6 100) mM, respectively (data not shown).
Previously, we noted that the binding of MgATP to the ArsA-
Sb(III) complex caused a triphasic quench in the tryptophan
fluorescence of Trp159 ArsA; and the rates of the three phases
were dependent upon the antimonite concentration, increas-
ing with Kd values of 50 (6 10), 100 (6 30), and 400 (6 100)
mM (27).
The kinetics of formation of the ArsA-MgADP-Sb(III) com-
plex are similar to those observed when Sb(III) was mixed with
ArsA/MgATP (27). The addition of MgATP to Trp159 ArsA
caused a transient increase in the tryptophan fluorescence,
which we attributed to the build up of the ArsA-MgADPzPi
complex. The addition of Sb(III) to this complex rapidly re-
versed the fluorescence enhancement, suggesting that Sb(III)
caused destabilization of the complex, and the rate of this
process increases in a hyperbolic manner with the Sb(III) con-
centration (i.e. kmax 5 99 s
21; kmin 5 ;1 s
21, and Kd 5 330 mM)
(27). EDTA was also able to reverse the enhanced fluorescence
of this pre-steady-state intermediate, with a rate constant of 4
s21, confirming that the intermediate was an ArsA-
Mgznucleotide complex that could be destabilized by withdraw-
ing Mg21 (27). Consistent with this interpretation, pre-equili-
brating the Trp159 ArsA with Sb(III), to form the ArsA-Sb(III)
complex, prevented formation of the transient with enhanced
fluorescence upon the addition of MgATP. However, in the
present investigation with Trp141 ArsA, Sb(III) did not reverse
the decrease in fluorescence that occurs upon formation of the
ArsA-MgADP complex but caused about a further 6% decrease
in fluorescence, indicative of the formation of the ArsA-
MgADP-Sb(III) complex. This behavior suggests that Sb(III)
specifically destabilizes the ArsA-MgADPzPi complex.
Mg21 Binding to the ArsA-ADP-Sb(III) Complex—As shown
in Fig. 10, there was little difference in the signal amplitudes
for the binding of Mg21 to the ArsA-ADP and ArsA-ADP-Sb(III)
complexes, apart from a 3% decrease in signal in increasing the
Sb(III) concentration from 25 to 2500 mM. These traces indicate
that the quench in fluorescence produced by the binding of
Sb(III) to ArsA-MgADP is not in fact additive but tends to
reduce slightly the overall signal that predominantly arises
from the addition of Mg21 to the complex. The formation of the
ArsA-MgADP-Sb(III) complex occurred at a slower rate than
that of the ArsA-MgADP complex, but there was no apparent
dependence upon the Sb(III) concentration, and the rate of the
fastest phase varied nonsystematically between 220 and 340
s21 (data not shown).
4 Since the data were suggestive of tight-binding, we also fitted it to
a quadratic equation for a second-order binding process, but this yielded
an identical value for the Kd.
FIG. 9. The antimonite concentration dependence of the rate
and amplitude of the signal associated with formation of the
ArsA-MgADP-Sb(III) complex due to the binding of Sb(III) to the
ArsA-MgADP complex. A series of stopped-flow records were gener-
ated by mixing ArsA, equilibrated with 1 mM ADP, 5 mM MgCl2, with
Sb(III), at the indicated concentration, in a stopped-flow device. The
rate (A) and amplitude (B) of the fluorescence signal for the formation
of the ArsA-MgADP-Sb(III) complex are plotted as a function of the
antimonite concentration. The curves through the data points are the
best fits to a hyperbolic equation, indicating values of 80 (6 10) s21, 3
(6 1) s21, and 60 (6 20) mM for kmax, kmin, and Kd, respectively, in A; and
of 30 mM (6 3) and 5.7% (6 0.1) for the Kd and maximal fluorescence
change (Fmax) in B.
FIG. 10. The binding of Mg21 to the ArsA-ADP-Sb(III) complex.
A set of semi-logarithmic plots of stopped-flow traces generated by
mixing 5 mM Mg21 with 5 mM ArsA, 1 mM ADP, equilibrated with 0 mM
Sb(III) (A), 25 mM Sb(III) (B), and 2500 mM Sb(III) (C) are shown.
Changes in the ArsA fluorescence were recorded with Ex 5 292.5 nm
and Em . 335 nm. One vertical division represents a fluorescence
change of 2.5%. The smooth curve through each trace are the best fits
to 4-exponential equations yielding rate constants of 460 (6 30), 142 (6
2), and 0.40 (6 0.03), and 0.027 (6 0.003) s21 (A); 270 (6 10), 71 (6 2),
2.0 (6 0.1), and 0.067 (6 0.003) s21 (B); and 269 (6 4), 30 (6 1), 2.0 (6
0.1), and 0.049 (6 0.002) s21 (C). The measured fluorescence changes
were 23 (A), 25 (B), and 22% (C).
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Mg21 Dissociation from the ArsA-MgADP-Sb(III) Complex—
The effects of Sb(III) upon the rate of MgADP dissociation were
investigated by dissociating the ArsA-MgADP complex with
EDTA in the presence of Sb(III). The stopped-flow trace shown
as Fig. 7C indicated that Sb(III) slowed the rate of dissociation
of the complex, and the trace was best fit to a double exponen-
tial with rate constants of 2.5 and 0.5 s21, respectively (cf. 2.5
versus 7 s21). Although the total signal amplitude was almost
equivalent to that in the absence of Sb(III) (cf. 20 versus 22%),
the relative proportions of the two phases had changed to 0.65
and 0.35 for the fast and slow phases, respectively (cf. 0.9 and
0.1, respectively, for the ArsA-MgADP complex, Fig. 7B).
Clearly, the implication is that Sb(III) retards dissociation of
Mg21 from the ArsA-MgADP complex. However, we found that
the signal amplitude was reduced in the presence of Sb(III). To
investigate this phenomena more fully, the experiment was
repeated for a series of Sb(III) concentrations. Although the
rate constants for the two phases remained constant with in-
creasing antimonite concentrations (e.g. phase 1 and 2 varied
between 2 and 3 and 0.5–1.5 s21, respectively; data not shown),
the signal amplitude decreased from 22 to 8% in a hyperbolic
manner, with a Kd of 260 (6 30) mM
5 (Fig. 11A). Although the
binding of Sb(III) to the ArsA-MgADP complex induces a
quench in the tryptophan fluorescence of the complex, this is
less than 6%. Moreover, the binding of Mg21 to the ArsA-ADP
and ArsA-ADP-Sb(III) complexes produced a similar quench in
protein fluorescence (see Fig. 10). The reduced signal ampli-
tude for the EDTA-induced dissociation of the ArsA-MgADP
complex in the presence of Sb(III) cannot simply be accounted
for by formation of the ArsA-ADP-Sb(III) complex, with re-
duced fluorescence, at the end of the reaction. A simple inter-
pretation of this behavior is that the ArsA-MgADP-Sb(III) com-
plex has less MgADP bound at the start of the reaction than the
ArsA-MgADP complex. This is probably due to antimonite act-
ing differentially at the two nonequivalent NBS of ArsA, trig-
gering release of MgADP from one site but retarding release
from the other site. Consistent with this interpretation, Fig.
11A establishes that in the presence of Sb(III) the reduction in
signal is attributable to a decrease in the amplitude of the fast
phase, rather than an equal reduction in both the fast and slow
phases. If the fast and slow phases were attributed to the
dissociation of MgADP and a subsequent conformational
change in the unliganded ArsA, respectively, then a reduction
in the amount of bound MgADP would, as observed, only de-
crease the amplitude of the fast phase.
Dissociation of the ArsA-MgMANT-ADP Complex—While
monitoring the MgADP induced changes in the tryptophan
fluorescence of Trp141, ArsA may predominantly report on
events occurring at the A1 NBS, studies of the changes in the
fluorescence of MANT-ADP have the potential to report on both
the A1 and A2 NBS. Consequently, the displacement of MANT-
ADP bound to ArsA should resolve both the A1 and A2 NBS if
they differ in their affinities. In contrast to the ArsA-MgADP
complex, dilution of the ArsA-MgMANT-ADP complex was suf-
ficient to induce its dissociation (Fig. 12A, trace B), with ADP
apparently serving to displace more of the bound MANT-ADP
(e.g. the signal increased from 11 to 24%; Fig. 12A, trace D).
From a simplistic point of view these results support our hy-
pothesis, with MgMANT-ADP rapidly dissociating from the low
affinity site upon dilution, but MgADP displacement needed to
dissociate the MgMANT-ADP from the high affinity site. How-
ever, the dilution might only be sufficient to dissociate partially
the ArsA-MgzMANT-ATP complex. The dissociation of MANT-
ADP was multiphasic, and a 4-exponential equation gave the
best fit, indicative of four phases with t1⁄2 ;10, ;50, and ;500
ms and ;9 s, respectively. Only the amplitudes of the fastest
two phases increased significantly when ADP was used to
dissociate the complex, and we attribute phase 1 and 2 to
MANT-ADP dissociation from the low and high affinity sites,
respectively. After dilution of the ArsA-MgMANT-ADP com-
plex with buffer the high affinity site would be expected to
retain more MANT-ADP than the low affinity site. Conse-
quently, the amplitude of phase 1 would be greater than that of
phase 2 after dilution with buffer, but the amplitude of phase 2
should increase after dilution with MgADP. Consistent with
this prediction, ADP caused a larger increase in the amplitude
of phase 2 (e.g. 5-fold) compared with phase 1 (e.g. 2-fold), so
that the two phases had nearly equal amplitudes (e.g. 7.9 and
7.7% fluorescence change for phases 1 and 2, respectively) and5 A second set of data yielded a half-saturation constant of 170 mM.
FIG. 11. The antimonite concentration dependence of the
EDTA-induced dissociation of the ArsA-MgADP-Sb(III) com-
plex. A series of stopped-flow records were generated by mixing by
mixing 5 mM ArsA, 0.5 mM ADP, 5 mM MgCl2, equilibrated with the
indicated concentrations of Sb(III), with 20 mM EDTA in a stopped-flow
device. These traces were fitted to a double exponential equation, and in
the upper panel, the amplitudes of the fast (E) and slow (f) phases and
the total amplitude (l ) are plotted as a function of the antimonite
concentration. For comparison, the amplitudes of the corresponding
phases for the dissociation of the ArsA-MgADP complex in the absence
of Sb(III) are shown on the plot as the large symbols l , , f, respec-
tively. The curve through the data points for the decrease in total
amplitude is the best fit to a hyperbolic equation, indicating that the
fluorescence decreases from 22 (6 1) to 8.0% (6 0.3) with a Kd 260 mM
(6 30). This decrease in fluorescence is clearly attributable to a de-
crease in the fast phase, with the slow phase remaining constant. In the
lower panel the corresponding rate constants for the fast ( l ) and slow
(E) phases are shown.
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constituted 66% of the total signal. EDTA-induced dissociation
of the complex caused a small and rapid decrease in fluores-
cence but was followed by an increase in fluorescence; we
attribute this behavior to the rapid dissociation of the ArsA-
MgMANT-ADP complex followed by the re-binding of MANT-
ADP to form the ArsA-MANT-ADP complex (Fig. 12A, trace A).
If antimonite enhances the dissociation of MgADP from one
site but retards its dissociation from the other, then we might
expect that the rates of phases 1 and 2 observed for MgMANT-
ADP dissociation would increase and decrease, respectively.
The dissociation of MANT-ADP from the ArsA-MgMANT-ADP-
Sb(III) complex was characterized by a 19% decrease in MANT
fluorescence that could be adequately fitted to a triple expo-
nential function with similar rate constants to those deter-
mined for phases 2–4 in the absence of Sb(III) (Fig. 12A, trace
C). To optimize this analysis, we optimized the signal using a
10-fold higher concentration of ArsA, for which the larger sig-
nal could be more clearly resolved into its constituent phases.
When 50 mM ArsA, 62.5 mM MANT-ADP, 5 mM MgCl2 was
mixed with 2.5 mM ADP, 5 mM MgCl2, the fast phase was
clearly resolved into two phases, with rate constants of 67 (6 1)
and 11.0 (6 0.3) s21 (Fig. 12B, trace A). In the presence of
antimonite the faster of the two phases was clearly absent, and
the slower phase occurred with a rate constant of 12.0 (6 0.2)
s21 (Fig. 12B, trace B). The effect of antimonite was to abolish
the fast phase, and we attribute this behavior to Sb(III)-in-
duced dissociation from the low affinity site. Although compli-
cated by the multiphasic traces, these results are highly con-
sistent with our conclusion that the ArsA NBS are
nonequivalent, one site allowing rapid release of nucleotides
and the other slow release, and that antimonite acts differen-
tially on these sites causing product dissociation from the low
affinity site.
MgADP Binding to the ArsA-Sb(III) Complex—Since our
studies indicated that antimonite amplifies the difference in
affinities of the two NBS for MgADP, we decided to determine
the kinetics of MgADP binding to the ArsA-Sb(III) complex.
The binding of (1 mM) MgADP to the ArsA-Sb(III) complex was
characterized by a multiphasic decrease in the tryptophan flu-
orescence of ArsA (Fig. 13). There was a very rapid decrease in
fluorescence (e.g. phase 1, t1⁄2 ,2 ms), which we attribute to the
binding of MgADP to the ArsA-Sb(III) complex, followed by a
slow decrease over several seconds (e.g. phases 3 and 4, t1⁄2 ,0.4
and 15 s, respectively). As the Sb(III) concentration was in-
creased we observed the progressive appearance of a phase of
intermediate rate (e.g. phase 2, t1⁄2 ;10–20 ms). The stopped-
flow traces were best fit to a 4-exponential function. As shown
in Fig. 14A, for increasing Sb(III) concentrations, an increase in
the amplitude of phase 2 was concomitant with a decrease in
that for phase 4. The amplitude of phase 1 was independent of
the Sb(III) concentration, as expected for a fixed MgADP con-
centration, as was that of phase 3. In contrast, only the rate
constants for phases 1 and 3 had a dependence upon the Sb(III)
concentration, with those for phase 1 and 3 decreasing and
increasing, respectively, with increasing concentration (Fig.
14B).
The hyperbolic decrease in the rate of ternary complex for-
mation (e.g. phase 1) suggests that the ArsA alternates be-
tween conformations that differ in their affinities for Sb(III)
and MgADP and that this transition is rate-limiting for forma-
tion of the ArsA-MgADP-Sb(III) ternary complex (30, 31). The
forward and backward rate constants for the transition and the
apparent affinity for Sb(III) can be determined from an inverse
hyperbolic function (Equation 5),
kobs 5 kf 1
kr z Kapp
[Sb(III)] 1 Kapp
(Eq. 5)
A fit of the phase 1 rate data (l ) in Fig. 14B to Equation 5
indicated values for kf, kr, and Kapp of 490 (6 10) s
21, 310 (6 20)
s21, and 140 (6 40) mM, respectively. The simplest mechanism
consistent with this kinetic behavior would be one in which
FIG. 12. Dissociation of the ArsA-MgMANT-ADP complex. A,
five semi-logarithmic plots of stopped-flow traces generated by mixing 5
mM ArsA, 25 mM MANT-ADP, 5 mM MgCl2 with 20 mM EDTA (trace A);
5 mM ArsA, 25 mM MANT-ADP, 5 mM MgCl2 with buffer (trace B); 5 mM
ArsA, 25 mM MANT-ADP, 5 mM MgCl2, 0.5 mM Sb(III) with 2.5 mM ADP,
5 mM MgCl2 (trace C); 5 mM ArsA, 25 mM MANT-ADP, 5 mM MgCl2 with
2.5 mM ADP, 5 mM MgCl2 (trace D); and 5 mM ArsA, 5 mM MgCl2 with
25 mM MANT-ADP, 2.5 mM ADP, 5 mM MgCl2 (trace E) are shown.
Changes in the ArsA fluorescence were recorded with Ex 5 292.5 nm
and Em . 420 nm, and one vertical division represents a fluorescence
change of 2.5%. The smooth curve through trace D is the best fit to a
4-exponential equation with rate constants of 71 (6 2) s21 (7.9% fluo-
rescence change), 13.0 (6 0.4) s21 (7.7% fluorescence change), 1.50 (6
0.04) s21 (4.8% fluorescence change), and 0.060 (6 0.001) s21 (3.4%
fluorescence change). The curve through trace B is a fit to a 4-exponen-
tial equation in which the rate constants were held constant at the
values derived from trace D, so as to allow a comparison of the ampli-
tudes of the four phases in each trace. This procedure yielded ampli-
tudes of 3.5, 1.6, 3.2, and 2.4% for phases 1–4, respectively, for trace B.
Trace C could be adequately fitted by a triple exponential function, with
rate constants of 14.0 (6 0.3), 1.10 (6 0.02), and 0.080 (6 0.001) s21, as
shown by the smooth curve through the trace, indicating the absence of
fast phase 1. B, two semi-logarithmic plots of stopped-flow traces gen-
erated by mixing 50 mM ArsA, 62.5 mM MANT-ADP, 5 mM MgCl2 with
2.5 mM ADP, 5 mM MgCl2 (A); and 50 mM ArsA, 62.5 mM MANT-ADP, 5
mM MgCl2, 0.5 mM Sb(III) with 2.5 mM ADP, 5 mM MgCl2 (B). The
smooth curve through trace A is the best fit to a 4-exponential equation
with rate constants of 67 (6 1), 11.0 (6 0.3), 1.30 (6 0.03), and 0.080 (6
0.002) s21. Trace B could be adequately fitted by a triple exponential
function, with rate constants of 12.0 (6 0.2), 0.60 (6 0.01), and 0.050 (6
0.001) s21, as shown by the smooth curve through the trace, indicating
the absence of fast phase 1.
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Sb(III) and MgADP compete for binding to ArsA. However, as
discussed above, Sb(III) does not reverse the quenched fluores-
cence of the ArsA-MgADP complex, but subsequent treatment
with EDTA does reverse the quench, indicating the formation
of an ArsA-MgADP-Sb(III) ternary complex. Moreover, recent
crystallographic studies have revealed the existence of the
ArsA-MgADP-Sb(III) ternary complex (25). A more elaborate
model of ternary complex formation is required, and we propose
the following Scheme 3:
If ArsA1 has a greater affinity than ArsA2 for Sb(III) (e.g. 1/K1
, 1/K6), then the binding of Sb(III) will sequester the ArsA in
the ArsA1 conformation. On the other hand, if ArsA2-Sb(III)
has a greater affinity than ArsA1-Sb(III) for MgADP, then the
binding of MgADP will tend to sequester the ArsA in the ArsA2
conformation. The fact that ArsA2-MgADP-Sb(III) exists im-
plies that 1/K7 , 1/K1. If the transition between ArsA
1-Sb(III)
and ArsA2-Sb(III) is rate-limiting, then the rate of ternary
complex formation (kobs) is approximated by Equation 5, with kf
; k4, kr ; k24, and Kapp ; K2. In the absence of Sb(III) ArsASCHEME 3
FIG. 13. The binding of MgADP to the ArsA-Sb(III) complex. A
set of semi-logarithmic plots of stopped-flow traces generated by mixing
5 mM ArsA, 1 mM ADP, 5 mM Mg21 with 25, 100, 150, 200, 375, and 750
mM Sb(III) are shown in A. The traces are arranged from top to bottom
in order of increasing Sb(III) concentration, with the top trace corre-
sponding to the lowest Sb(III) concentration. Changes in the ArsA
fluorescence were recorded with Ex 5 292.5 nm and Em . 335 nm. One
vertical division represents a fluorescence change of 2.5%. The smooth
curve through the traces generated with 25 mM (top trace) and 750 mM
(bottom trace) Sb(III) are the best fits to 3- and 4-exponential equations
in B and C, respectively. For the 3-exponential analyses in B, there is
clearly a systematic deviation of the fitted curves about the measured
curves indicate the inadequacy of this fit to the data. The 4-exponential
analyses in C yielded rate constants of 740 (6 20), 58 (6 5), 0.770 (6
0.002), and 0.005 (6 0.001) s21 for 25 mM Sb(III); and 460 (6 12), 46 (6
1), 2.060 (6 0.003), and 0.005 (6 0.001) s21 for 750 mM Sb(III).
FIG. 14. The antimonite concentration dependence rate and
amplitude of the signal associated with formation of the ArsA-
MgADP-Sb(III) complex due to the binding of MgADP to the
ArsA-Sb(III) complex. A series of stopped-flow records were gener-
ated by mixing ArsA, equilibrated with the indicated concentrations of
Sb(III), with 1 mM ADP, 5 mM MgCl2 in a stopped-flow device. These
traces were fitted to a 4-exponential equation, and the amplitude (A)
and log of the rate (B) for each phase are plotted as a function of the
antimonite concentration; the symbols used for phases 1–4 are l , E, ,
and , respectively. The curves through the phase 2 (E) and 4 () data
points in A are the best fits to hyperbolic equations, indicating Kd
values of 200 (6 20) and 180 (6 30) mM, respectively. The curves
through the phase 1 ( l ) and 3 () data points in B are the best fits to
hyperbolic equations (e.g. Equations 5 and 1, respectively), indicating
values for kmax (or kf), kmin (or kr), and Kd of 490 (6 10) s
21, 310 (6 20)
s21, and 140 (6 40) mM; and 1.7 (6 0.2) s21, 0.5 (6 0.2) s21, and 200 (6
100) mM, respectively.
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exists as an equilibrium mixture of 61% ArsA1-MgADP and
39% ArsA2-MgADP.
The hyperbolic decrease in the rate of phase 1 indicates that
the ArsA alternates between conformations that differ in their
affinities for antimonite and the nucleotide, and this behavior
can be interpreted in terms of Scheme 3, but can this scheme
account for the other phases? The rates of phases 2 and 4 are
independent of the antimonite concentration, suggesting that
these are attributable to isomerizations of the ArsA-MgADP-
Sb(III) complex, whereas the rates of phases 1 and 3 are de-
pendent upon the antimonite concentration, suggesting that
they are attributes of the binding of antimonite. One possibility
is that phase 1 is due to formation of the ArsA1-Sb(III) complex
and phase 2 to formation the ArsA1-MgADP-Sb(III) complex. If
the ArsA1-Sb(III) and ArsA2-Sb(III) complexes have a similar
fluorescence then the amplitude of phase 1 would be independ-
ent of the concentration of Sb(III), but the rate would decrease
hyperbolically because the ArsA2-Sb(III) to ArsA1-Sb(III) tran-
sition is rate-limiting for the binding of Sb(III). On the other
hand, if the ArsA1-MgADP-Sb(III) complex has a lower fluores-
cence than the ArsA-Sb(III) complexes, and our studies indi-
cate that it does, then the amplitude of phase 2 would increase
as the concentration of the ArsA1-Sb(III) complex increases
with the Sb(III) concentration; and the rate of ArsA1-MgADP-
Sb(III) complex formation would be concentration-independent
for a fixed concentration of MgADP. Similarly, phases 3 and 4
can be attributed to formation of the ArsA2-Sb(III) and ArsA2-
MgADP-Sb(III) complexes. However, the binding of Sb(III) to
ArsA2 is probably rate-limited by a slow isomerization follow-
ing formation of the ArsA2-Sb(III) complex, which is rapid but
slower than the ArsA1 to ArsA2 transition. The amplitude of
phase 4 decreases with the Sb(III) concentration as more of the
ArsA is sequestered in the ArsA1 conformation by Sb(III). In-
deed, the decrease in the amplitude of phase 4 mirrors the
increase in the amplitude of phase 2, providing strong evidence
that Sb(III) pulls ArsA between two mutually exclusive confor-
mations. A consequence of this interpretation is that the rate of
phase 1 and the amplitudes of phases 2 and 4 should all be
determined by the affinity of ArsA2 for Sb(III) (e.g. K2 in
Scheme 3). Consistent with this prediction, fits of the ampli-
tude data for phases 2 and 4 to hyperbolic equations yielded
apparent Kd values of 200 (6 20) and 180 (6 30) mM, respec-
tively, which are similar to the value of 140 (6 40) mM obtained
from the rate data for phase 1 (Fig. 14). An inconsistency with
this interpretation is that in applying Equation 5, a simplifying
assumption is made that the ArsA2 state has no affinity for
Sb(III), but the rate data for phase 3, which should provide a
measure of the affinity of ArsA2 for Sb(III), indicated that this
state has moderate affinity for Sb(III) (e.g. Kd 5 200 (6 100)
mM). However, the ArsA1 state need only have a higher affinity
than ArsA2 for Sb(III) to sequester the protein in this confor-
mation. This aside, the data clearly indicate that ArsA can
adopt different conformations that are stabilized by MgADP
and Sb(III) to different extents. We have observed similar
kinetic behavior for the binding of Mg21 to the ArsA-ATP-
Sb(III) complex, with the rate of formation of the ArsA-ATP-
Sb(III) complex decreasing in a hyperbolic manner with in-
creasing Sb(III) concentration (27). Although indicative of the
transition between nucleotide and antimonite-stabilized con-
formations, this transition was much slower (e.g. kf 5 1 s
21 and
kr 5 0.5 s
21), and the antimonite favored conformation had a
higher affinity of 65 mM for antimonite (27).
The Pre-steady-state Production of Pi—In view of the fact
that the present investigation indicated that the NBS of ArsA
are nonequivalent and differentially affected by antimonite,
we decided to reinvestigate the kinetics of ATP hydrolysis
using a Pi assay initiated by mixing ArsA with MgATP/
Sb(III) in a stopped-flow device (see under “Materials and
Methods” for the details of the assay). This stopped-flow
experiment revealed a biphasic burst in the production of Pi
that resulted from ATP hydrolysis by ArsA. Following a lag in
activity of about 40 ms, presumably attributable to the time
taken for formation of the catalytic complex, there was a
burst in Pi production over the following 100 ms (e.g. k 5 47
s21) and a second burst was apparent over 10 s (e.g. k 5 0.2
s21). Both bursts were of a similar amplitude, with the pro-
duction of 6 and 7 mM Pi per mM of ArsA, indicating that the
ArsA turns over several times before the steady-state inter-
mediate builds up to a rate-limiting concentration. In con-
trast, ArsA equilibrated with Sb(III) produced a fast burst,
with a similar rate constant and amplitude, but the slow
burst phase was absent, being replaced by an apparent lag in
activity that was most pronounced during the first 2 s of the
FIG. 15. Phosphate burst phase of ArsA ATPase. 10 mM ArsA was
mixed with 1 mM ATP in a stopped-flow device, and the release of
phosphate was monitored spectrophotometrically as the change in ab-
sorbance at 360 nm associated with the phosphorolysis of 2-amino-6-
mercapto-7-methylpurine by phosphate. This experiment was per-
formed in the presence of 0.5 mM Sb(III), equilibrated with either the
ATP (traces A) or ArsA (traces B), or in the absence of Sb(III) (traces C).
A and B show the production of Pi over the first 140 ms and 100 s of the
reaction, respectively. Two bursts in Pi production, over 100 ms and
20 s, could be resolved when the ArsA was simultaneously mixed with
ATP and Sb(III); and thereafter Pi production was linear over the next
80 s, but extended analyses established that Pi production remained
linear over 1000 s. The data between 40 and 250 ms were fitted to a
single-exponential function, and the data between 0.25 and 90 s were
fitted to a single exponential function with a linear term. This analysis
indicated that the fast and slow burst phases occurred with apparent
rate constants and amplitudes of 49 (6 1) s21 and 74.0 (6 0.1) mM and
0.20 (6 0.03) s21 and 71 (6 1) mM, respectively, and with a steady-state
release of phosphate at a rate of 6 mM21 ArsA.
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reaction (Fig. 15A, trace B). Furthermore, when Sb(III) was
omitted from the reaction, there was no fast burst, and the
slow burst was not readily apparent over this 100-s time base
(Fig. 15B, trace C). Previously, in the absence of Sb(III), we
noted a slow burst in Pi release of about 2 nmol Piznmol
21
ArsA, which occurred over 2000 s, with a rate constant of
0.001 s21 (26). This behavior indicates that antimonite rap-
idly activates both NBS, so that they can hydrolyze MgATP,
with several molecules undergoing hydrolysis in a burst of
activity. In our previous analysis of the ATPase mechanism,
we postulated that following product release, a conforma-
tional transition of the ArsA back to its original conformation
was rate-limiting for steady-state ATP hydrolysis in the ab-
sence of Sb(III). The present study suggests more complex
behavior because several turnovers are necessary to allow
the build up of an ArsA conformation that rate-limits the
steady state. An interesting possibility, which has been pro-
posed for other ATPases
(31), is the trapping of an ArsAzMgADPzPi intermediate
(Scheme 4),
If product release from ArsA occurs at a faster rate than for-
mation of the ArsAzMgADPzPi intermediate, then several turn-
overs will occur before all the ArsA becomes trapped in this
state, after which subsequent turnovers will be rate-limited by
the dissociation of the ArsA*-MgADPzPi complex (e.g. k2r).
Equilibration of the ArsA with antimonite leads to further
activation of the site that turns over slowly, so that MgATP
turnover is no longer rate-limited by a step subsequent to
hydrolysis. Indeed, the slow burst phase is replaced by an
activity lag, which correlates with the time taken for the tran-
sition between the conformations stabilized by MgATP and
Sb(III), respectively (27). A simple mechanism for Sb(III) to
activate the ATPase would be for antimonite to cause an in-
crease in k2r, so that the ArsA*-MgADPzPi intermediate does
not build up. In the present investigation we have provided
evidence that Sb(III) destabilizes an ArsA-MgADPzPi complex,
possibly ArsA*-MgADPzPi.
DISCUSSION
Most ATP-driven efflux pumps have a quaternary structure
in which there are two nucleotide-binding sites (NBS), both of
which are required for ATPase and transport activity. An un-
derstanding of how these sites interact is fundamental to an
understanding of the molecular events involved in the action of
these pumps. Previously, we have undertaken a rigorous anal-
ysis of the kinetics of the binding of the substrate ATP to the
ArsA ATPase. This analysis was facilitated using a derivative
of ArsA that contains a single tryptophan residue, Trp159,
which is optically responsive to the binding of ATP but much
less so to the binding of the product ADP (28). Herein we report
on the use of another derivative of ArsA that contains a single
tryptophan residue, Trp141, which is more responsive to the
binding of ADP than ATP (28). These tryptophan residues span
the DTAP region, which connects the allosteric soft metal-
binding site with the nucleotide-binding site, in the A1 half of
ArsA. The binding of MgATP to Trp159 ArsA induces a tran-
sient increase in the tryptophan fluorescence, and we have
attributed the slow decay in fluorescence to a conformational
re-arrangement of ArsA that follows product release, and the
protein adopts its original unliganded conformation. The bind-
ing of MgADP to Trp141 ArsA induces a quench in the trypto-
phan fluorescence; and herein we report on a detailed investi-
gation of the kinetics of MgADP binding to Trp141 ArsA, and we
compare this with MgATP binding to Trp159 ArsA.
The initial ArsA-nucleotide complexes formed with MgATP
and MgADP are of a similar affinity (cf. 620 versus 600 mM), but
overall ArsA has a higher affinity for MgATP over MgADP (cf.
430 versus 760 mM). In both cases, the formation of the initial
complex is rate-limited by a subsequent conformational
change, but is 4 orders of magnitude faster for the ArsA-
MgADP complex. This isomerization, which may result from
closure of the NBS, will have the effect of tightening the bind-
ing of the nucleotide, indicating apparent Kd values of 230 and
30 mM for MgATP and MgADP, respectively. We attribute the
difference between these values and the measured Kd values
(e.g. 230 versus 430 mM for MgATP and 760 versus 30 mM for
MgADP) to the ArsA alternating between conformations that
differ in their affinities for the Mg-nucleotide (see kinetic
Scheme 2).
The two different forms of ArsA (e.g. ArsA1 and ArsA2 in
Scheme 2) may represent open and closed conformations of the
nucleotide-binding site (NBD). This prediction is consistent
with the recently determined structure of ArsA, which revealed
MgADP locked into the A1 NBD but free to diffuse from the A2
NBD (25). This is an interesting observation because in the
present study we have found that MANT-ADP-induced disso-
ciation of MgADP is rapid, with a koff .223 s
21, but the MANT-
ADP used to displace ADP might only do so at a single site, the
A2 NBS. Furthermore, a 20-fold lower concentration of Mg-
MANT-ADP can replace bound MgADP on ArsA, indicating
that MANT-ADP is bound with higher affinity than MgADP.
On the other hand, whereas the ArsA-MgMANT-ADP complex
readily dissociates upon dilution, the ArsA-MgADP complex
does not, and EDTA is required to dissociate the ArsA-MgADP
complex, indicating that MgADP is bound more tightly than
MgMANT-ADP. Furthermore, EDTA-induced dissociation of
the ArsA-MgADP complex occurs at a much slower rate than
koff for MANT-ADP displacement (e.g. 6.6 s
21 versus .223 s21).
A simple and reasonable explanation of this anomalous behav-
ior is that MANT-ADP displaces ADP from the A2 NBS,
whereas EDTA induces MgADP dissociation from the A1 NBS.
Consistent with this interpretation, an additional fast phase is
observed when MgADP is used to displace MgzMANT-ADP
from ArsA. These experiments are also consistent with earlier
UV-activated nucleotide cross-linking studies that suggested
that the A1 NBS is a high affinity, poorly exchangeable site,
whereas the A2 NBS is a low affinity, easily exchangeable site
(24). An interesting proposal is that the binding of nucleotides
to the A1 and A2 sites is mutually exclusive, with, for example,
the binding of nucleotide to the A1 site transiently locking the
ArsA in an A1 closed/A2 open (e.g. ArsA1) conformation.
Antimonite affects the distribution of the two different con-
formational forms of ArsA by preferentially stabilizing one
conformation. Moreover, the kinetics of the binding of MgADP
to the ArsA-Sb(III) complex strongly suggests that Sb(III) se-
questers the ArsA in one of two mutually exclusive conforma-
tions (e.g. the ArsA1-MgADP-Sb(III) complex). Most notably,
the appearance of the phase attributed to formation of ArsA1-
MgADP-Sb(III) mirrors the disappearance of that attributed to
formation of the ArsA2-MgADP-Sb(III) complex (Fig. 14). The
Sb(III) stabilized conformation is one in which there is en-
hanced and retarded release of nucleotides from the low and
high affinity sites, respectively. An obvious interpretation of
these data is that Sb(III) stabilizes the ArsA1 conformation in
which the A1 NBS is closed and the A2 NBS is open. The
demonstration of both a fast and slow burst in Pi production is
SCHEME 4
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consistent with two catalytic sites of high and low affinity (Fig.
15). The site that produces the slow burst is activated by Sb(III)
so that ATP hydrolysis at this site is no longer rate-limited by
steps subsequent to the hydrolysis step. The stabilization of the
ArsA1 conformation provides a mechanism for activation by
stabilizing the open conformation of the A2 site, so that product
dissociation from this site is no longer rate-limiting.
Interestingly, we find that the binding of Sb(III) to the ArsA-
MgADP complex, and of MgATP to the ArsA-Sb(III) complex, is
triphasic, and the rate of each phase is dependent upon the
antimonite concentration; indicative of three ArsA-MgNucle-
otide-Sb(III) complexes, with Kd values of about 50, 100, and
400 mM. We previously proposed that these might be slowly
inter-converting complexes, but the recent determination of the
structure of the ArsA-MgADP-Sb(III) complex has revealed
that three antimonite molecules are bound to ArsA in the
complex. One Sb(III) is bound to His148 (A1) and Ser420 (A2),
one to Cys113 (A1) and Cys422 (A2), and one to Cys172 (A1) and
His453 (A2). This suggests a physical interpretation of the ki-
netic behavior; each antimonite complex results from the addi-
tion of an antimonite molecule to ArsA as the high, medium,
and low affinity sites are successively filled. Clearly, it is
tempting to speculate on whether these antimonite complexes
play differential roles in controlling the affinities and activities
of the A1 and A2 NBDs. Mutagenesis experiments point toward
a differential role; mutation of His148 and His453 to alanines
resulted in a 5-fold reduction in the affinity for metal-stimu-
lated ATP hydrolysis,6 whereas significantly more severe were
mutations of the cysteine ligands. The Cys1133 Ser and Cys172
3 Ser proteins exhibited a 20-fold increase in the concentration
of antimonite required for half-maximal activation, whereas
the Cys422–Ser protein exhibited a 200-fold increase (33). The
Pi burst experiments reported herein indicate that Sb(III) has
three major effects as follows: stimulation of the A1 and A2
NBS, so that they under go a burst in Pi production during a
multiple turnover event, followed by further activation of the
A2 site, so that product dissociation is no longer rate-limiting.
An interesting proposal is that the binding of successive anti-
monite molecules, which progressively increase the A1-A2 in-
teractions, controls these events. We note that the high, inter-
mediate, and low affinity ArsA-MgATP complexes are formed
at rates that differ by more than an order of magnitude be-
tween each complex, so that they are formed successively in
time. Only formation of the high affinity complex occurs at a
rate that could control the fast burst phase. The rate of forma-
tion of the intermediate affinity complex, but not the low affin-
ity complex, is sufficiently fast to control the slow burst, and
formation of the low affinity complex the activation of the low
affinity NBS. However, no slow burst occurs when ArsA is
equilibrated with Sb(III) prior to mixing with MgATP, suggest-
ing that the binding of the second antimonite may control
activation of the low affinity NBS.
The structure and function of ArsA are suggestive of the
following model of the events occurring at the NBS. In the
absence of ligands, ArsA oscillates between two conformations
as follows: ArsA1 in which the A1 site is closed and the A2 site
open, and ArsA2 in which the A1 site is open and the A2 site
closed. MgATP can bind to either conformation with the distri-
bution of conformers dependent upon the affinities of the A1
and A2 sites. However, the binding of Sb(III) to the high affin-
ity antimonite-binding site sequesters the ArsA into the ArsA1
conformation. This triggers a burst in MgATP hydrolysis at the
A1 site, catalyzing the build up of a pre-steady-state interme-
diate that rate-limits further turnover. Since Sb(III) hinders
the dissociation of MgADP from the high affinity NBS, this
suggests that the intermediate is ArsA-MgADP. Why should
Sb(III) activate the A1 NBS? One possibility is that the hydrol-
ysis of MgATP during the burst phase is required to drive a
conformational change in the ArsA. This conformational
change could involve an enhancement in the interaction of the
A1 and A2 domains, possibly leading to formation of the inter-
mediate antimonite-binding site. Similarly, the binding of
Sb(III) to this site may be necessary to drive a further confor-
mational change, activating the A2 site so that it can catalyze
the rapid hydrolysis of MgATP, leading to a further tightening
of the A1-A2 domain interaction and formation of the low
affinity antimonite-binding site. The binding of Sb(III) to this
site triggers the rapid release of product MgADP. In other
words, the three Sb(III) ions “zip” the A1 and A2 domains
together, ‘locking’ ArsA in the activated form, in which there is
continuous rapid hydrolysis of MgATP at the A2 NBS. This
must be coupled to the pumping of Sb(III) molecules across the
membrane, but how?
The structure of ArsA indicates that the buried surface be-
tween the A1 and A2 domains is relatively small compared
with the total surface of the enzyme, such that ArsA is essen-
tially a hollow protein with a large central cavity (25). The
metal-binding site is open below this central cavity, and it is
sealed above by the loop between helices H9 and H10 that
provide the ligand Cys172. Thus, it is possible that during the
catalytic cycle of ArsA antimonite ions may access the metal
site from the central cavity, to then be injected into ArsB in
association with a conformational change in the H9-H10 region
(33). ArsA would then be similar to a “pumping heart” that
expands while drawing antimonite ions from the cytoplasm and
contracts while expelling them into the membrane channel
provided by ArsB. To achieve this pump action, the ArsA must
bind and release Sb(III) ions into the ArsB channel. The hy-
drolysis of MgATP at the A2 site may drive the ArsA between
conformations that have high and low affinity for antimonite.
In this context, we note that the affinity of ArsA for Sb(III) is
increased by the binding of Mgznucleotides. Could the three
antimonite sites be used to relay the Sb(III) ion through ArsA
to ArsB? The release of MgADP from the A2 NBS could trigger
a reduction in the affinity of the “high affinity” binding site for
Sb(III), allowing its release to ArsB, but this site can only be
refilled by Sb(III) from the intermediate affinity site, and the
intermediate site by Sb(III) from the low affinity site, thus
providing a mechanism to draw Sb(III) into ArsA and eject it
into the ArsB channel. In effect, the two Pi burst phases are
required to “prime the pump” with Sb(III).
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